Literature DB >> 2463094

Interferon is able to reduce tumor cell susceptibility to human lymphokine-activated killer (LAK) cells.

A Grönberg1, M Ferm, L Tsai, R Kiessling.   

Abstract

It is known that IL-2 induces lymphocytes to produce interferon-gamma (IFN-gamma) and this IFN type is particularly efficient in inducing tumor cell resistance to natural killer (NK) cell-mediated lysis. We have investigated the effect of IFN on tumor cell sensitivity to LAK cell-mediated cytotoxicity. Pretreatment of the human K562 leukemia and HHMS melanoma with IFN-gamma and the Daudi lymphoma with IFN-alpha caused a significant reduction in sensitivity to lysis by human LAK cells generated in vitro in the presence of human recombinant IL-2 (100 U/ml). The LAK activity was mediated by cells expressing NK cell markers (CD16,NKH1) as well as by cells with T cell markers (CD3, CD5). IFN-treated K562 cells were protected from lysis mediated by all these populations. Supernatants from LAK cultures containing IFN-gamma were able to induce NK and LAK resistance when used to pretreat K562 overnight. Antibodies to IFN-gamma but not to IFN-alpha were able to neutralize this activity. Taken together, these results indicate that the production of IFN-gamma by LAK cells may be of importance in induction of tumor cell resistance to LAK cell-mediated lysis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2463094     DOI: 10.1016/0008-8749(89)90353-5

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  5 in total

1.  IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism.

Authors:  Karl-Johan Malmberg; Victor Levitsky; Håkan Norell; Cristina Teixeira de Matos; Mattias Carlsten; Kjell Schedvins; Hodjattallah Rabbani; Alessandro Moretta; Kalle Söderström; Jelena Levitskaya; Rolf Kiessling
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

2.  Induction and abrogation of LACK reactive cells in the evolution of human leishmaniasis.

Authors:  K Maasho; D Wolday; M Edjigu; K Söderström; S Britton; H Akuffo
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

3.  Role of adhesion molecules in lymphokine-activated killer cell killing of bladder cancer cells: further evidence for a third ligand for leucocyte function-associated antigen-1.

Authors:  A M Jackson; A B Alexandrov; S Prescott; K James; G D Chisholm
Journal:  Immunology       Date:  1992-06       Impact factor: 7.397

4.  Diverse effect of cytokine treatment of tumor cells on specific versus non-specific cytotoxicity.

Authors:  H Naganuma; E Halapi; G Masucci; M Hansson; P Wersäll; C Hising; S Venkateswaran; H Mellstedt; R Kiessling
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

5.  Decrease in lymphokine-activated killer sensitivity of a human renal-cell carcinoma cell line after cytokine treatment.

Authors:  M Yanase; T Tsukamoto; Y Kumamoto; K Kato; Y Hashimoto
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.